6th Edition of Molecular Biology of the Cell Now Available

Posted on by

The most recent edition of Molecular Biology of the Cell is now available at the MSK Library.  As with previous editions, Molecular Biology of the Cell, Sixth Edition distills a vast amount of scientific knowledge into concise principles and enduring concepts.  The Sixth Edition has been extensively revised and updated with the latest research in the field of cell biology, and it provides an exceptional framework for teaching and learning.

As a new feature, each chapter now contains intriguing open-ended questions highlighting “What We Don’t Know,” introducing students to challenging areas of future research. All of this new material features clear writing and is accompanied by beautiful illustrations.

The 6th edition of Molecular Biology of the Cell can be found in Tri-Cat, our library catalog.

Precision Medicine, a New 3-D Vaccine, Supplements and More…

Posted on by

Here are a few highlights of cancer research news that have recently caught my attention:

  • The NIH has developed a site that outlines President Obama’s Precision Medicine Initiative. The NIH will also be hosting a workshop on February 11-12 to discuss the opportunities and challenges around building a large research cohort focused on precision medicine.
  • Key breast cancer genes reveal distinctions between African-American women and European-American women. The study involved 1,275 European-American and 1,299 African-American women. Read more on the findings in the International Journal of Cancer.
  • Four major retailers have been ordered by the New York Attorney General’s office to cease selling some of their store brand supplements. In tests, supplements from GNC, Target, Walmart and Walgreens were found lacking the advertised ingredients frequestly. Dr. David S. Seres, Director, Medical Nutrition, Associate Professor of Medicine in the Institute of Human Nutrition weighed in on the issue in an editorial piece for CNN.

Continue reading →

Funding Opportunity from the Leukemia & Lymphoma Society

Posted on by

There’s still a few days left to submit your letter of intent for the Translational Research Program (TRP) offered by the Leukemia & Lymphoma Society.

Applications are sought proposing novel approaches to the prevention, diagnosis or treatment of leukemia, lymphoma and myeloma. Proposals should be based on molecular, cellular or integrated systems findings and be conceptually innovative. The program is intended to cover an initial three year period (with two year renewal) and will provide support for work which is clinical in orientation with an overall goal to result in a clinical trial and/or TRP renewal.

Letters of intent are due by 3:00 pm on February 17, 2015. For more information, see the TRP Guidelines & Instructions for fiscal year 2015.